Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Cusi

Showing results (51-60 of 189) with videos related to

Pageof 19
Sort By:
Obesity (Silver Spring, Md.)|September 23, 2021
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver diseaseDiana Barb, Enrico M Repetto, Michael E Stokes, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2024
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variantsFernando Bril, Srilaxmi Kalavalapalli, Romina Lomonaco, et al.
The Journal of Clinical Endocrinology and Metabolism|September 10, 2004
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetesMandeep Bajaj, Swangjit Suraamornkul, Sangeeta Kashyap, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 8, 2014
A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical studyMarina Kawaguchi-Suzuki, Fernando Bril, Paola Portillo Sanchez, et al.
Plos One|June 2, 2021
Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetesKristin Alexandra Dayton, Fernando Bril, Diana Barb, et al.
Nutrition Research (New York, N.Y.)|March 20, 2021
Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosisMark D DeBoer, Boya Lin, Stephanie L Filipp, et al.
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|February 9, 2022
Real-World Experience With Automated Insulin Pump Technology in Veterans With Type 1 DiabetesMorolake Amole, Loren Whyte, Hans K Ghayee, et al.
Diabetes|January 29, 2002
Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetesThongchai Pratipanawatr, Kenneth Cusi, Peter Ngo, et al.
Frontiers in Pharmacology|August 2, 2018
A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic SteatohepatitisMarina Kawaguchi-Suzuki, Kenneth Cusi, Fernando Bril, et al.
Journal of Investigative Medicine High Impact Case Reports|July 28, 2017
The Yin and Yang Between Plasma Glucose Levels and Cortisol Replacement Therapy in Schmidt's SyndromeChristopher A Newton, Eleni Sheehan, Kathleen Wyne, et al.
Pageof 19

Showing results (51-60 of 189) with videos related to

Sort By:
Pageof 19
Obesity (Silver Spring, Md.)|September 23, 2021
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver diseaseDiana Barb, Enrico M Repetto, Michael E Stokes, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2024
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variantsFernando Bril, Srilaxmi Kalavalapalli, Romina Lomonaco, et al.
The Journal of Clinical Endocrinology and Metabolism|September 10, 2004
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetesMandeep Bajaj, Swangjit Suraamornkul, Sangeeta Kashyap, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 8, 2014
A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical studyMarina Kawaguchi-Suzuki, Fernando Bril, Paola Portillo Sanchez, et al.
Plos One|June 2, 2021
Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetesKristin Alexandra Dayton, Fernando Bril, Diana Barb, et al.
Nutrition Research (New York, N.Y.)|March 20, 2021
Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosisMark D DeBoer, Boya Lin, Stephanie L Filipp, et al.
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|February 9, 2022
Real-World Experience With Automated Insulin Pump Technology in Veterans With Type 1 DiabetesMorolake Amole, Loren Whyte, Hans K Ghayee, et al.
Diabetes|January 29, 2002
Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetesThongchai Pratipanawatr, Kenneth Cusi, Peter Ngo, et al.
Frontiers in Pharmacology|August 2, 2018
A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic SteatohepatitisMarina Kawaguchi-Suzuki, Kenneth Cusi, Fernando Bril, et al.
Journal of Investigative Medicine High Impact Case Reports|July 28, 2017
The Yin and Yang Between Plasma Glucose Levels and Cortisol Replacement Therapy in Schmidt's SyndromeChristopher A Newton, Eleni Sheehan, Kathleen Wyne, et al.
Pageof 19